New Jersey Assembly Bill A1909

New Jersey 2024-2025 Regular Session

• Introduced: 1/9/24
• Refer: 1/9/24

Caption

Limits amount paid by covered persons for purchase of insulin drugs and epinephrine; requires Division of Consumer Affairs to investigate insulin prices.

Impact

The implications of A1909 are significant for both consumers and insurers operating in New Jersey. By capping the amount paid for insulin and epinephrine, the law seeks to enhance access to these critical medications and promote health equity among residents. This measure may lead to reduced emergency medical costs associated with insulin and epinephrine access issues, as individuals are more likely to afford their necessary prescriptions. Additionally, the bill requires the Division of Consumer Affairs to investigate the pricing practices of prescription drugs, which may lead to further reforms in how medications are priced and sold in the state.

Summary

Assembly Bill A1909 aims to limit the out-of-pocket costs for covered persons in New Jersey when purchasing insulin drugs and epinephrine auto-injectors. Specifically, the bill stipulates that individuals should not pay more than $100 for a 30-day supply of insulin or for a package of two epinephrine devices. This legislation is designed to address the rising costs of these essential medications that are vital for individuals with diabetes and severe allergies, respectively. The bill's sponsors argue that such limitations are necessary to alleviate financial burdens on consumers who rely on these medications to manage their health conditions.

Contention

While the bill has garnered support from various health advocacy groups and members of the legislature who emphasize the importance of affordable healthcare, it may face challenges regarding its implementation. Insurance providers could express concerns over the financial implications of capping drug costs, which might affect their pricing models and profit margins. Furthermore, the investigation into drug pricing practices mandated by the bill may uncover systemic issues that could provoke opposition from pharmaceutical companies if they perceive threats to their pricing structures. As the bill progresses, the debates surrounding these dynamics will be crucial in shaping the final form and effectiveness of the legislation.